Overview

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Formoterol Fumarate
Pharmaceutical Solutions